source
- ARPA-H awards $160 M to accelerate bespoke gene‑editing therapies for rare diseasesARPA-H announced a $160 million, five‑year investment through its THRIVE program to speed the development of personalized gene‑editing treatments for rare genetic conditions. The awardees include…
- FDA proposes streamlined registration rule for hub-and-spoke drug manufacturing networksThe FDA released a proposed rule that would let distributed drug manufacturing facilities using a hub-and-spoke model register as a single establishment. Under current regulations each site must r…